Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer

4 Jan 2019

Abstract excerpt

BACKGROUND: Utilization of alternative transcription start sites through alterations in epigenetic promoter regions causes reduced expression of immunogenic N-terminal peptides, which may facilitate immune evasion in early gastric cancer. We hypothesized that tumors with high alternate promoter utilization would be resistant to immune checkpoint inhibition in metastatic gastric cancer. PATIENTS AND METHODS: Two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Chromatin Remodeling and Cancer
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30624548
DOI: 10.1093/annonc/mdy550

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancerPMID 30624548Read ↗

Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibitionSemantic proximity Read ↗

Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapiesSemantic proximity Read ↗

Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor microenvironment in advanced gastric cancer: a phase II chemoimmunotherapy trialSemantic proximity Read ↗

Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor immune microenvironment in advanced gastric cancer: A phase II chemoimmunotherapy trialSemantic proximity Read ↗

Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci.Semantic proximity Read ↗

Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment.Semantic proximity Read ↗

An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.Semantic proximity Read ↗

Systematic profiling of alternative splicing in Helicobacter pylori-negative gastric cancer and their clinical significanceSemantic proximity Read ↗

Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements.Semantic proximity Read ↗

Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic CarcinomaSemantic proximity Read ↗

Chromatin Accessibility Regulates Gene Expression and Correlates With Tumor-Infiltrating Immune Cells in Gastric AdenocarcinomaSemantic proximity Read ↗

Alterations in Intratumoral Immune Response Before and Early-on-Treatment of Nivolumab in Unresectable Advanced or Recurrent Gastric CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.